total src (Cell Signaling Technology Inc)
Structured Review
Total Src, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 227 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/total+src/Src+Mouse+mAb/pmc12925544-188-7-23
Average 95 stars, based on 227 article reviews
Images
Related Articles
other:Article Title: Signaling and transcriptional dynamics underlying early adaptation to oncogenic BRAF inhibition Article Snippet: Antibodies against phospho-SRC (Y416), total SRC, and Article Title: High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma Article Snippet: Western Blot analyses were performed with standard techniques using the following antibodies: β-Actin, total Src, phosphoSrc (T416), phospho-ERK1/2 (T202/204), total and phospho-Akt (S473), total and phospho-S6 (S240/244), phospho-mTOR (S2448), phospho-4EBP1(T37/46), Article Title: Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC Article Snippet: The following antibodies were used for Western Blot Analysis: At 1:1000 Total Western Blot:Article Title: Narciclasine as a potential therapeutic agent to overcome EGFR-TKI resistance in non-small cell lung cancer. Article Snippet: .. Primary antibodies against total EGFR (#4267, Cell Signaling Technology(CST)), CDK1 (#9116, CST), phospho-EGFR Y1068 (#44-788 G, Invitrogen), total STAT3 (#4904, CST), phospho-STAT3 Y705 (#9145, CST), phospho-Src (#6943,CST), Article Title: Narciclasine as a potential therapeutic agent to overcome EGFR-TKI resistance in non-small cell lung cancer Article Snippet: .. Primary antibodies against total EGFR (#4267, Cell Signaling Technology(CST)), CDK1 (#9116, CST), phospho-EGFR Y1068 (#44-788 G, Invitrogen), total STAT3 (#4904, CST), phospho-STAT3 Y705 (#9145, CST), phospho-Src (#6943,CST), |
